The Emerging Link Between Hypogonadism and Metabolic Syndrome

Guay, André T.

doi:10.2164/jandrol.108.006015

Cited by 45 publications

(30 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There seems to be an interrelationship between hypogonadism and MS (25). Several cross-sectional studies report increased prevalence of hypogonadism in MS (8, 9, 11), while many others report increased prevalence of MS and diabetes mellitus in subjects with lower testosterone levels (12)(13)(14)(15).…”

Section: Discussionmentioning

confidence: 99%

“…Thus, our data are noteworthy as they show poor metabolic parameters in a sizeable group of treatment-naïve patients with CHH, mentioning that hypogonadism can cause MS even in very young ages. Testosterone replacement is expected to improve the metabolic abnormalities in patients with hypogonadism (25), and for some authors, it may be a novel treatment option in MS (26). However, reports about the metabolic effects of testosterone replacement are controversial.…”

Section: Discussionmentioning

confidence: 99%

“…Testosterone replacement is an emerging treatment option for the metabolic abnormalities in patients with hypogonadism (25,26). However, not all the data is in favor of the benefits of testosterone replacement.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

Sönmez¹,

Haymana²,

Bolu³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: The relationship between metabolic syndrome (MS) and hypogonadism has always been investigated in study groups confounded with aging, obesity or chronic metabolic disorders. So far, there has been no data about the presence of MS in young hypogonadal patients. Also, there is controversial data about the metabolic effects of testosterone replacement therapy. We investigated the frequency of MS in treatment-naïve, young men with congenital hypogonadal hypogonadism (CHH). We also searched for the effect of testosterone replacement on the metabolic profiles of this specific patient group. Design: Retrospective analysis. Methods: A total of 332 patients (age 21.68G2.09 years) were enrolled. The control group included 395 age-and body mass index (BMI)-matched healthy young men (age 21.39G1.49 years). Standard regimen of testosterone esters (250 mg/3 weeks) was given to 208 patients. Results: MS was more prevalent in CHH (P!0.001) according to healthy controls. The patients had higher arterial blood pressure, waist circumference (WC), triglyceride (P!0.001 for all), fasting glucose (PZ0.02), fasting insulin (PZ0.004), homeostatic model assessment of insulin resistance (HOMA-IR) (PZ0.002) and lower high density lipoprotein (HDL) cholesterol (P!0.001) levels. After 5.63G2.6 months of testosterone treatment, the BMI, WC (P!0.001 for both), systolic blood pressure (PZ0.002) and triglyceride level (PZ0.04) were increased and the total and HDL cholesterol levels were decreased (PZ0.02 and P!0.001 respectively). Conclusions: This study shows increased prevalence of MS and unfavorable effects of testosterone replacement in young patients with CHH. Long-term follow-up studies are warranted to investigate the cardiovascular safety of testosterone treatment in this specific population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

Sönmez¹,

Haymana²,

Bolu³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…A link between the metabolic syndrome and hypogonadism has been suggested (Guay et al, 2009) and it has been shown that nearly all aspects of the metabolic syndrome are associated with reduced testosterone levels (Phillips et al, 2003;Svartberg et al, 2004;Stellato et al, 2000). A crosssectional study showed that men with low testosterone levels have a higher prevalence of metabolic syndrome (Muller et al, 2005).…”

Section: Hypogonadism Metabolic Syndrome and Prostate Cancermentioning

confidence: 99%

Prostate Cancer and Metabolic Syndrome: Is there a link?

McGrowder¹,

Jackson²,

Crawford³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Metabolic syndrome has become quite prevalent within our society. Over the past two decades, the prevalence of metabolic syndrome has sharply increased worldwide and it has become a major public health problem in several countries. It is associated with the global epidemic of obesity and diabetes mellitus and imposes numerous cardiovascular risks. Prostate cancer is the second most common cancer among men, surpassed only by non-melanoma skin cancer. A considerable body of evidence exists suggesting that some components of the metabolic syndrome have been associated with the risk of prostate cancer. These components include obesity, an abdominal fat distribution, and hyperinsulinemia. Androgen deprivation therapy (ADT) is the most widely used therapeutic modality in prostate cancer. It changed the body composition and lipid profile of men with prostate cancer. Androgen deficiency is associated with increased levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, increased production of proinflammatory factors, and increased thickness of the arterial wall and contributes to endothelial dysfunction. The aim of this review is to evaluate the association between metabolic syndrome and prostate cancer and to discuss the implications of androgen deficiency in men with cardiovascular risk factors. A comprehensive literature search was carried out with the use of PubMed from 1980 through 2011, and relevant articles pertinent to metabolic syndrome and prostate cancer are evaluated and discussed.

show abstract

“…Na população geral, a deficiência androgêni-ca pode contribuir para o surgimento de alterações no perfil glicídico e lipídico (16). Em obesos, níveis séricos de testosterona se correlacionam inversamente com a obesidade visceral, a síndrome metabólica, a resistência à insulina (17), a hipertensão arterial, os níveis baixos de HDL-c e a hipertrigliceridemia (18).…”

Section: Discussionunclassified